www.ijarp.com ISSN 2456-9992 Page: 01-05

International Journal Advanced Research Publications

Review Article

Volume: 02
Issue: 03

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): A REVIEW OF PATHOPHYSIOLOGY, RISK FACTORS AND MANAGEMENT

Abidah Akhter*[1], Ms. Tanya Sharma[2], Dr. Peeyush Jain[3]

[1]Bachelor of Pharmacy Student, Department of Pharmaceutical Sciences, Mewar University, Gangrar, Chittorgarh, Rajasthan, India.

[2]Head of Department (HOD), Department of Pharmaceutical Sciences, Mewar University, Gangrar, Chittorgarh, Rajasthan, India.

[3]Principal, Department of Pharmacy (DOP), Mewar University, Gangrar, Chittorgarh, Rajasthan, India.

Article Received: 3 February 2026, Article Revised: 23 February 2026, Published on: 16 March 2026

***Corresponding Author: Abidah Akhter**

Bachelor of Pharmacy Student, Department of Pharmaceutical Sciences, Mewar University, Gangrar, Chittorgarh, Rajasthan, India.

DOI: https://doi-doi.org/101555/ijarp.3328

ABSTRACT

Chronic Obstructive Pulmonary Disease (COPD) is a progressive and life-threatening respiratory disorder characterized by persistent airflow limitation and chronic inflammatory responses in the lungs. COPD is primarily caused by long-term exposure to harmful particles such as cigarette smoke, environmental pollutants, and occupational dust. The disease includes pathological conditions such as chronic bronchitis and emphysema. COPD significantly contributes to global morbidity and mortality, placing a substantial burden on healthcare systems. This review article highlights the epidemiology, risk factors, pathophysiology, clinical manifestations, diagnosis, and current management strategies for COPD. Early diagnosis, smoking cessation, and appropriate pharmacological therapy remain essential for reducing disease progression and improving patient outcomes.

KEYWORDS: COPD, chronic bronchitis, emphysema, airflow limitation, bronchodilators, respiratory disease.

1. INTRODUCTION

Chronic Obstructive Pulmonary Disease (COPD) is one of the most common chronic respiratory diseases worldwide. It is characterized by persistent respiratory symptoms and

irreversible airflow obstruction. According to the World Health Organization, COPD is among the leading causes of death globally and is projected to become the third leading cause of death by 2030.

COPD is primarily associated with chronic exposure to harmful particles such as tobacco smoke. However, environmental pollution, occupational hazards, and genetic predisposition also contribute to disease development. COPD is a preventable and treatable disease, but early detection is crucial to prevent irreversible lung damage.



2. Epidemiology

COPD affects millions of individuals worldwide. It is more common in individuals over 40 years of age and in those with a history of long-term smoking. The prevalence of COPD continues to rise due to increasing exposure to risk factors and aging populations.

Developing countries experience higher COPD prevalence due to indoor air pollution caused by biomass fuel combustion used for cooking and heating.

3. Risk Factors

Several risk factors contribute to COPD development:

3.1 Smoking

Cigarette smoking is the most significant risk factor responsible for approximately 80–90% of COPD cases.

3.2 Air Pollution

Exposure to environmental pollutants, including particulate matter and toxic gases, increases the risk of COPD.

3.3 Occupational Exposure

Workers exposed to chemicals, dust, and industrial fumes are more susceptible to developing COPD.

3.4 Genetic Factors

Deficiency of alpha-1 antitrypsin is a genetic condition that predisposes individuals to early-onset COPD.

3.5 Respiratory Infections

Frequent respiratory infections during childhood may impair lung development and contribute to COPD later in life.

4. Pathophysiology

COPD is characterized by chronic inflammation of the airways, lung parenchyma, and pulmonary vasculature. Inflammatory cells such as neutrophils, macrophages, and lymphocytes play a crucial role in the disease process.

Chronic exposure to irritants leads to structural changes in the lungs including:

Narrowing of small airways

Destruction of alveolar walls (emphysema)

Increased mucus secretion

Reduced lung elasticity

These pathological changes result in airflow limitation and impaired gas exchange.

5. Clinical Manifestations

Patients with COPD commonly present with the following symptoms:

Persistent cough

Excessive sputum production

Shortness of breath (dyspnea)

Wheezing

Chest tightness

Reduced exercise tolerance

Symptoms usually worsen gradually and may lead to acute exacerbations requiring hospitalization.

6. Diagnosis

The diagnosis of COPD is based on clinical symptoms and pulmonary function testing.

6.1 Spirometry

Spirometry is the gold standard diagnostic test for COPD. It measures the ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC).

6.2 Imaging

Chest X-ray and CT scans help assess lung damage and detect complications.

6.3 Laboratory Tests

Blood tests may help identify alpha-1 antitrypsin deficiency in suspected genetic cases.

7. Management and Treatment

7.1 Non-Pharmacological Management

Smoking cessation

Pulmonary rehabilitation

Oxygen therapy

Vaccination (influenza and pneumococcal vaccines)

7.2 Pharmacological Treatment

Bronchodilators

Bronchodilators such as beta-2 agonists and anticholinergic agents are the first-line treatment for COPD.

Corticosteroids

Inhaled corticosteroids help reduce airway inflammation.

Phosphodiesterase-4 Inhibitors

These drugs reduce inflammation and improve lung function in severe COPD cases.

Combination Therapy

Combination inhalers containing bronchodilators and corticosteroids are widely used to improve therapeutic outcomes.

8. Prevention

Preventive strategies play an essential role in reducing COPD incidence:

Avoiding tobacco smoking

Reducing exposure to environmental pollutants

Using protective equipment in occupational settings

Early diagnosis and management

9. CONCLUSION

COPD remains a major public health challenge worldwide. Smoking is the most significant risk factor associated with disease development. Early detection, lifestyle modification, and appropriate pharmacological management are essential to reduce disease progression and improve patient quality of life. Future research should focus on developing novel therapeutic strategies and improving preventive measures to combat this chronic respiratory disorder.

REFERENCES

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for COPD Management and Prevention. 2023.
2. World Health Organization. Chronic Obstructive Pulmonary Disease (COPD). WHO Report.
3. Barnes PJ. Chronic Obstructive Pulmonary Disease. New England Journal of Medicine. 2000.
4. Vogelmeier CF et al. Global Strategy for Diagnosis, Management and Prevention of COPD. American Journal of Respiratory and Critical Care Medicine.
5. Rang HP, Dale MM, Ritter JM. Rang and Dale's Pharmacology. Elsevier.
6. Katzung BG. Basic and Clinical Pharmacology. McGraw Hill.
7. Brunton LL et al. Goodman and Gilman's Pharmacological Basis of Therapeutics.
8. Decramer M, Janssens W. COPD Pathogenesis. Lancet.
9. Barnes PJ. Inflammatory Mechanisms in COPD. Chest Journal.
10. Hogg JC et al. Pathology of COPD. Annual Review of Pathology.